Greece's Cannabis Paradox: Booming Medical Exports, Strict Criminal Law

Photo by Efrem Efre via Pexels.

Drive an hour south of Corinth and you'll find a 56,000 square meter facility in Examilia where a subsidiary of Israeli cannabis company Tikun Olam grows, dries, and processes medical cannabis destined for pharmacies in Berlin and Zurich. Drive into any Greek city on a Friday night and a young person caught with a rolled joint in their pocket is still looking at a misdemeanor charge under a criminal code that predates the entire medical program. These two realities exist in the same country, under the same government, often enforced by the same police force.

It took seven years to get from the initial policy decision to an actual prescription being filled at a Greek pharmacy counter. The joint ministerial decision that reclassified cannabis came down in July 2017. The first domestically grown, domestically processed medical cannabis product didn't reach a pharmacy shelf until February 19, 2024. In the interim, Greece built out an entire regulatory apparatus, attracted foreign cultivation investment, and started exporting cannabis to countries with more permissive consumer markets than its own -- all while leaving the underlying criminal statute for personal possession essentially untouched.

As of mid-2026, there's no decriminalization bill working its way through the Hellenic Parliament. The regulatory activity happening right now is aimed at the industrial and medical side of the plant, and even there, the newest draft legislation tightens consumer-facing rules rather than loosening them. Greece has built something unusual: a serious, EU-facing cannabis export industry sitting directly on top of an unreformed criminal framework for the people who actually live there.

How Greece Got Here: From Table A to a Regulated Industry

Photo by Hans Reniers via Unsplash.

Greece's cannabis reform started with a narrow, technical move rather than a sweeping legalization. In July 2017, the Health Ministry and Justice Ministry issued a joint ministerial decision reclassifying cannabis from Table A -- the category reserved for drugs considered to have no accepted medical use -- down to Table B, the tier that includes substances with recognized therapeutic value. That reclassification didn't legalize anything on its own, but it opened the legal door for everything that followed.

The first concrete legislative step came in 2018 with Law 4523/2018, which permitted the cultivation and processing of cannabis containing up to 0.2% THC -- essentially an industrial hemp framework, useful for fiber and low-THC extracts but nowhere near what a medical cannabis patient would need. The real expansion arrived in 2021, when a new bill extended legalization to the cultivation, processing, and sale of medical marijuana above that 0.2% threshold, finally creating a legal category for actual medicinal-strength product grown on Greek soil.

What makes the Greek model distinctive, though, is what lawmakers did next. Article 71 of Law 4864/2021 amended the country's foundational drug law, Law 4139/2013, to explicitly ban the import of medical cannabis products. That's a striking choice for a country trying to build a pharmaceutical industry from scratch -- it meant Greece couldn't simply bring in finished product from established producers in Canada, the Netherlands, or Israel to supply its own patients while domestic cultivation ramped up. Instead, every gram of medical cannabis legally sold in Greece today has to be grown, processed, and finished within Greek borders. That single provision shaped the entire subsequent build-out: it's the reason foreign cannabis companies had to physically relocate cultivation and processing operations onto Greek land rather than simply importing into the market, and it's a big part of why the industry that exists today looks less like a distribution business and more like an agricultural manufacturing sector.

The Licensing Maze: EOF Approval and Triple Ministry Sign-Off

Photo by Bastian Riccardi via Pexels.

Getting a medical cannabis product onto a Greek pharmacy shelf isn't like registering a supplement or an herbal tincture. Greek law treats these products as finished pharmaceuticals, full stop, which means they're subject to the same rigor as any other prescription drug. That classification decision alone explains a lot of the delay between legislative authorization and actual patient access.

The first gate is EOF, the Ethnikos Organismos Farmakon, Greece's National Organisation for Medicines. A company can't sell anything without full marketing authorization from EOF, which involves the standard pharmaceutical dossier requirements around quality, safety, and manufacturing consistency that any drug maker has to clear.

But EOF approval of the product itself is only half the process. Separately, a company needs an establishment approval and an operational licence just to run the facility where the cannabis is grown and processed. That operational licence isn't a single-agency sign-off -- it requires simultaneous approval from three different ministries: Development and Investment, Health, and Rural Development and Food. Each ministry is evaluating a different piece of the puzzle -- economic development criteria, public health safeguards, and agricultural/rural land-use compliance -- and all three have to align before a cultivator can legally operate.

Stack those two tracks together -- EOF's pharmaceutical product approval running alongside a triple-ministry facility licensing process -- and you get a system with a lot of sequential and parallel checkpoints, each with its own review timeline, documentation standards, and inspection requirements. That layered structure is the practical explanation for why it took until February 19, 2024 for the first domestically grown, domestically processed medical cannabis product to actually reach a pharmacy counter in Greece, a full seven years after the original 2017 reclassification decision. The legal framework existed years earlier; building an operation that could satisfy every checkpoint took considerably longer.

A Growing Export Business

Photo by Angeleses via Pixabay.

The slow bureaucratic start hasn't stopped the market from growing quickly once product actually started moving. Greece's medical cannabis market was valued at roughly $32 million in 2025, with projections putting it at $46.8 million in 2026 -- a jump of nearly 50% in a single year, which tells you the underlying demand and export pipeline are both scaling fast now that the licensing bottleneck has partially cleared.

Examilia, a small town in the Peloponnese near Corinth, has become the physical center of that growth. Tikun Olam's Greek subsidiary operates a 56,000 square meter cultivation and processing facility there -- large enough to function as a serious industrial-scale pharmaceutical cannabis operation rather than a boutique grow. The site handles everything from cultivation through processing, positioning it to supply both the domestic Greek market and, increasingly, buyers abroad.

That export activity is now real and growing. Tikun Olam shipped its first medical cannabis exports from Greece to Switzerland in November 2024, a milestone that validated the entire domestic-cultivation-only model Greek law had forced onto the industry -- product grown under EOF and ministry oversight in Examilia was good enough to clear Swiss import standards. Germany has emerged as an even bigger customer: Greece exported 49 kilograms of medical cannabis to Germany in the first quarter of 2025 alone.

That German demand isn't incidental. Germany overhauled its own medical and adult-use cannabis framework starting in 2024, and the resulting surge in domestic German demand has outpaced what German and other established European cultivators can supply on their own. Greece, with its combination of Mediterranean growing conditions, EU regulatory alignment, and a cultivation base built specifically because imports were banned, has positioned itself as one of the suppliers filling that gap. It's a genuinely interesting inversion -- a law written to force self-sufficiency ended up producing a surplus that gets exported to exactly the kind of countries Greece couldn't import from.

Recreational Use: Still a Criminal Offense

Greek law treats cannabis trafficking far more severely than simple possession: while possession carries a maximum of just 5 months, trafficking penalties start at 96 months and can extend to life imprisonment (999 months, used here to represent an effectively unlimited sentence).

None of the industrial growth described above touches the legal status of cannabis for ordinary personal use in Greece. Simple possession remains a criminal misdemeanor under Law 4139/2013, carrying a potential sentence of up to five months imprisonment. That's the law as written, and it applies regardless of how sophisticated the medical export sector next door has become.

In practice, first-time possession cases in Greek courts are almost always resolved with a suspended sentence or converted into a fine rather than actual jail time. But suspended doesn't mean erased -- the criminal charge is still filed, a record still exists, and the underlying legal exposure is real every time someone is caught. Greek police and prosecutors aren't treating personal cannabis possession as a priority crime, but they also aren't declining to charge it, and the statute gives them full authority to prosecute.

Where things get considerably more serious is trafficking. Greek law draws a sharp line based on quantity or value: once the amount or estimated market value of cannabis involved crosses 75,000 euros, the case escalates from a misdemeanor-adjacent matter into felony territory. Felony trafficking convictions carry sentences ranging from 8 years up to life imprisonment, along with fines that can reach as high as 300,000 euros. That's a serious cliff -- the gap between a suspended fine for personal possession and a potential life sentence for trafficking-level quantities is enormous, and it reflects how strictly Greek law still treats cannabis outside the narrow medical-pharmaceutical channel.

As of August 2026, there's no decriminalization bill or adult-use legalization proposal actively moving through the Hellenic Parliament. Every legislative energy currently being spent on cannabis policy is directed at the medical and industrial framework -- licensing, THC thresholds, export logistics -- not at the criminal code governing personal use. For a Greek citizen facing a possession charge today, the practical legal landscape looks essentially the same as it did before 2017.

April 2026: Tighter Rules, Not Looser Ones

Photo by Werner Pfennig via Pexels.

The clearest signal of where Greek cannabis policy is actually headed came in April 2026, when the Health Ministry opened public consultation on a draft law covering cannabis, nicotine, and tobacco as part of a broader package of healthcare reforms. The stakeholder consultation period ran through April 27, 2026, giving industry players, medical associations, and public health groups a formal window to weigh in before the bill advances further.

One piece of the draft looks like a loosening: it proposes raising the permitted THC threshold in cultivation from 0.2% to 0.3%, bringing Greece's cultivation standard closer in line with broader EU hemp regulations, which have generally moved toward that 0.3% benchmark in recent years. On its face, that's a technical adjustment that gives cultivators a bit more room and aligns Greek agricultural policy with its European neighbors.

But the same draft law pairs that adjustment with something much more restrictive on the consumer side: a full ban on the retail sale, supply, purchase, and use of dried cannabis flower. Read together, the two provisions send an unmistakable message. Greece is willing to give cultivators slightly more cannabinoid latitude for growing and processing purposes, but it is simultaneously moving to foreclose any possibility that flower -- the form of cannabis most associated with direct consumer and recreational use -- ends up legally available for sale or use in any retail context.

That's the opposite direction from where many European jurisdictions have been heading. Germany loosened its rules in 2024. The Netherlands has been running regulated cultivation pilots for coffeeshop supply. Greece's April 2026 draft moves the other way on the one product form ordinary consumers would actually recognize and want, even while making a technical concession on cultivation thresholds that mostly benefits growers and processors, not end users. The direction of travel is unambiguous: tighter controls on anything resembling consumer access, continued expansion on the industrial and export side.

Add it all up and Greece has made a coherent, if unstated, policy choice: cannabis is welcome as an industrial export commodity, grown under pharmaceutical-grade oversight and shipped to patients in Germany and Switzerland, but it is not welcome as something an ordinary Greek citizen can legally buy, hold, or smoke. Every major policy move since the 2017 reclassification -- the import ban that forced domestic cultivation, the triple-ministry licensing structure, the 2026 draft law's flower ban paired with a cultivation-threshold increase -- reinforces that same split rather than closing it.

Patients with valid prescriptions and the companies supplying them are operating in an increasingly mature, EOF-regulated system that's attracting real investment and generating real export revenue. Ordinary Greeks caught with cannabis for personal use, meanwhile, are still working through a criminal code written before any of this reform began, one that hasn't been meaningfully revisited even as the industry around it has scaled into tens of millions of dollars in annual market value.

The April 2026 draft law is worth watching closely precisely because it shows how deliberate this split is. Raising the THC cultivation threshold to 0.3% while simultaneously banning retail flower sale isn't a contradiction -- it's a clarification. Greece is telling growers they can operate with slightly more flexibility, and telling everyone else that the plant itself, in the form people actually recognize and want, is staying out of reach. Whatever happens next in Greek cannabis policy, expect the industrial and medical side to keep professionalizing while the personal-use side stays frozen exactly where it's been since before the reform era started.